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electrophysiology recording to determine the features that underpin its selectivity. An alanine scan 
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nAChR. Our computational models indicate that the first loop of ribbon AuIB binds in the "aromatic box" of 
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ABSTRACT 
The ribbon isomer of α-conotoxin AuIB has 10-fold greater potency than the wild-type 
globular isomer at inhibiting nicotinic acetylcholine receptors (nAChRs) in rat 
parasympathetic neurons, and unlike its globular isoform, ribbon AuIB only targets a specific 
stoichiometry of the α3β4 nAChR subtype. Previous electrophysiological recordings of AuIB 
indicated that ribbon AuIB binds to the α3(+)α3(−) interface within the nAChR extracellular 
domain, which is displayed by the (α3)3(β4)2 stoichiometry but not by (α3)2(β4)3. This 
specificity for a particular stoichiometry is remarkable and suggests that ribbon isoforms of α-
conotoxins might have great potential in drug design. In this study, we investigated the 
binding mode and structure-activity relationships of ribbon AuIB using a combination of 
molecular modeling and electrophysiology recording to determine the features that underpin 
its selectivity. An alanine scan showed that positions 4 and 9 of ribbon AuIB are the main 
determinants of the interaction with (α3)3(β4)2 nAChR. Our computational models indicate 
that the first loop of ribbon AuIB binds in the “aromatic box” of the acetylcholine orthosteric 
binding site, similar to that of globular AuIB. In contrast, the second loop and the termini of 
the ribbon isomer have different orientations and interactions in the binding sites to those of 
the globular isomer. The structure-activity relationships reported herein should be useful to 
design peptides displaying a ribbon α-conotoxin scaffold for inhibition of nAChR subtypes 
that have hitherto been difficult to selectively target.  
Abbreviations 
ACh, acetylcholine; AChBP, acetylcholine-binding protein; ECD, extracellular domain; 
gAuIB, globular AuIB; ICD, intracellular domain; nAChR, nicotinic acetylcholine receptor; 
rAuIB, ribbon AuIB; SAR, structure-activity relationship; TMD, transmembrane domain 
Keywords: Conotoxin; Nicotinic acetylcholine receptor; Biological activity; Molecular 
modeling 
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Introduction 
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated cation-
selective ion channels that belong to the Cys-loop family of receptors [1]. Neuronal nAChRs 
are homo- or heteropentamers of α2–α10 and β2–β4 subunits, and the different pentameric 
isoforms are differentially expressed in different parts of the brain [2,3]. Neuronal nAChR 
isoforms are involved in a range of diseases and conditions, including Alzheimer’s disease, 
Parkinson’s disease, schizophrenia, epilepsy, nicotine addiction, anxiety, depression and pain 
[3]. 
Heteropentameric nAChRs can assemble into different stoichiometries, with some 
displaying diverse pharmacological and biophysical properties [3]. For example, the α4β2 
nAChR subtype, which is the most abundant nAChR subtype in the human brain, exists in 
two main stoichiometries: (α4)2(β2)3 and (α4)3(β2)2 [4]. These two stoichiometries have 
contrasting pharmacological properties: the (α4)2(β2)3 has a long open lifetime and is 
insensitive to the agonist NS-9283, whereas the (α4)3(β2)2 has a short open lifetime and is 
potentiated by NS-9283 [4]. Subunit stoichiometries of other nAChR subtypes such as the 
α3β4, α7β2 and α9α10 nAChR have also been reported [5–7]. Although the various subunit 
stoichiometries of these nAChR subtypes have disparate functions, the relationship between 
the different functions and pathophysiology states remains unknown, mostly because 
detecting nAChR subtype stoichiometries is challenging. In this study we established some 
groundwork on the structure-activity relationship (SAR) of the ribbon isoform of α-conotoxin 
AuIB (rAuIB) [8,9], which specifically inhibits one of the two major stoichiometries of the 
α3β4 nAChR [10]. 
Structurally, nAChRs are composed of three domains: an extracellular domain (ECD), 
a transmembrane domain (TMD), and an intracellular domain (ICD), as shown in Fig. 1 
[1,11]. Acetylcholine (ACh) binds at the interface between two subunits in the ECD, 
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triggering the opening of the channel [1]. Each subunit in the ECD is composed of one α-
helix, which lines the pore, and two β-sheets made of 10 β-strands (Fig. 1A and B). The ACh 
orthosteric binding site is located at the interface between two subunits in the ECD; the 
“principal” subunit, denoted (+), contacts the agonist with the A-, B- and C-loops, and the 
“complementary” subunit, denoted (−), contributes to the ACh binding site through the β-
strands 2, 5 and 6 (Fig. 1B). Functional binding sites cannot be formed with β subunits as the 
principal subunit; therefore the number of functional binding sites displayed by 
heteropentameric nAChRs depend on their stoichiometries. As illustrated in Fig. 1C, the 
(α3)2(β4)3 nAChR subtype has two α3(+)β4(−) functional binding sites, and the (α3)3(β4)2 
subtype has an additional functional binding site between two α3 subunits, i.e. α3(+)α3(−) [6]. 
Concatemeric assemblies of α3 and β4 subunits with the arrangements described in Figure 1C 
were reported to have similar pharmacological properties to subtypes assembled freely from 
subunits expressed in oocytes [12]. We note that in the current study we focused on 
engineered α3-containing nAChRs of these compositions but in native tissue the ganglionic 
nAChRs are more complex and could include accessory subunits of α3, α5, α6, β2 or β4 [13]. 
Conotoxins are a large family of disulfide-rich peptides isolated from the venom of 
marine cone snails [14,15]. Due to their potency and exquisite selectivity for ion channels and 
transporters of the nervous system, these peptides are considered as valuable pharmacological 
tools and drug leads [16]. The largest characterized pharmacological class of conotoxins are 
the α-conotoxins, which inhibit nAChRs and typically have 12−20 amino acid residues 
[14,16]. Because of their small size, α-conotoxins can readily be chemically synthesized, and 
their selectivity and potency against important nAChR subtypes make them interesting 
candidate drug leads [16–18]. Most α-conotoxins have the cysteine pattern CC-C-C, 
corresponding to the conotoxin cysteine Framework I. These conotoxins are further classified 
into m/n groups according to the length of the two loops, which are defined as the segments 
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between Cys II and Cys III (loop 1, m residues) and between Cys III and Cys IV (loop 2, n 
residues) [19,20]. The four Cys residues can theoretically form three disulfide connectivities, 
resulting in the globular isomer (Cys I-III, Cys II-IV), ribbon isomer (Cys I-IV, Cys II-III) or 
bead isomer (Cys I-II, Cys III-IV) (Fig. 1D). The globular isomer is typically displayed by 
wild-type α-conotoxins isolated from venoms, apart from one instance where the ribbon 
connectivity of an α-conotoxin was detected in the venom of Conus imperialis [21]. Some 
ribbon isomers are as active as or more potent than the globular isomer at inhibiting nAChRs, 
and consequently display altered pharmacological properties [8,22].  
α-Conotoxin AuIB (Fig. 1D and E) belongs to the 4/6 class of conotoxins [9], and the 
globular form (gAuIB) inhibits the rat α3β4 nAChR with an IC50 of 1−3 µM [10]. rAuIB was 
the first ribbon isomer reported to have higher potency than the globular isomer, with rAuIB 
displaying a 10-fold improved inhibition of Ach-evoked current in rat parasympathetic 
neurons compared to gAuIB, with IC50s of 0.1 nM and 1.2 nM, respectively [8]. However, 
another study reported that gAuIB was more potent than rAuIB at inhibiting rat α3β4 nAChR 
expressed in Xenopus laevis oocytes [23]. These apparently conflicting results were explained 
by a switch in the major stoichiometry of the α3β4 nAChR when expressed in mammalian 
cells compared to X. laevis oocytes [6]. AuIB isomers were shown to have differential 
sensitivity to the two stoichiometries of the α3β4 nAChR: gAuIB inhibited the (α3)3(β4)2 
nAChR (transfected at 10:1 ratio) and (α3)2(β4)3 nAChR (1:10 ratio) with IC50s of 1.1 µM and 
3.0 µM, respectively; whereas rAuIB inhibited the (α3)3(β4)2 nAChR with an IC50 of 0.86 µM 
and was inactive at the other stoichiometry [10]. Therefore, rAuIB only inhibited the 
stoichiometry displaying an α3(+)α3(−) binding site, indicating that it binds at the interface 
between two α3 subunits. Conotoxin rAuIB can therefore potentially be used to identify a 
single subtype and stoichiometry among all α3β4 subtypes expressed in vivo. 
6 
 
As the α3β4 nAChR subtype is involved in a range of drug addictions, (e.g. for 
morphine [24], methamphetamine [25] and nicotine [26–28]), and the β4 subunit is linked to 
anxiety behavior [29], these receptors are of considerable pharmaceutical interest. Thus, high-
affinity molecular probes are required to tease apart the neurological functions of the two 
main α3β4 nAChR stoichiometries. Here, we investigated the SAR and binding mode of 
rAuIB on the rat α3β4 nAChR putatively expressed as (α3)3(β4)2 stoichiometry from the 
injection of 10:1 α3:β4 RNA ratio. This is the first detailed SAR study of the binding mode of 
a ribbon α-conotoxin. 
Materials and methods 
2.1 Peptide synthesis and cleavage  
A suite of 13 AuIB peptides (gAuIB, rAuIB, 10 Ala variants of rAuIB and 
[P7A]gAuIB) was synthesized using Fmoc solid phase peptide synthesis (SPPS) on a rink 
amide resin (Novabiochem®, Merck, Kenilworth, NJ, USA), with the side chains of Cys 
residues protected in pairs using orthogonal protective groups, which were then selectively 
removed in different oxidation solutions. For this purpose, we used the acid labile trityl (Trt) 
group to protect Cys II and Cys III, and the S-acetamidomethyl (Acm) group to protect Cys I 
and Cys IV for rAuIB and its mutants. Likewise for gAuIB, the Trt group was used to protect 
Cys II and Cys IV, and the Acm group was used to protect Cys I and Cys III. All crude linear 
peptides were cleaved and deprotected in a cleavage cocktail comprising 96% trifluoroacetic 
acid (TFA, Auspep, VIC, Australia), 2% H2O and 2% triisopropylsilane (v/v) for 2 h. The 
crude peptides were purified by HPLC using a gradient of 0−50% buffer B (0.045% TFA in 
90% acetonitrile [Merck]) over 50 min and monitoring at 214/280 nm. The same method was 
also used in subsequent purifications. 
A two-step oxidative folding was used to form the disulfide bonds; the first disulfide 
bond was formed by adding peptides (80 mg crude peptide dissolved in 100 mL water) into an 
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equal volume of 20 mM potassium ferricyanide, 0.1 M Tris, pH 7.5 for 1 h. The reaction 
mixture was frozen and lyophilized overnight, and the second disulfide bond was formed by 
adding 50 mL of 0.1 M iodine solution for 1 h. All Fmoc-amino acids were from Chem-Impex 
International (Wood Dale, IL, USA). All organic reagents and solvents, unless stated 
otherwise, were purchased from Sigma-Aldrich (St Louis, MO, USA).  
2.2 Nuclear magnetic resonance (NMR) spectroscopy 
With a few exceptions, where crystallization has been possible [30], NMR is the 
preferred technique for conotoxin structural characterization. Two-dimensional total 
correlation spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy (NOESY) 
spectra of rAuIB, gAuIB and the variants were acquired using an Avance-600 MHz NMR 
spectrometer (Bruker) with mixing times of 80 ms and 200–300 ms, respectively. The α-
proton (Hα) chemical shifts of synthetic peptides were assigned using CcpNmr analysis 
(version 2.4.1). Subsequently, the differences between the observed Hα chemical shifts and 
those of the corresponding residues in a random coil peptide [31], referred to as secondary Hα 
chemical shifts, were calculated to provide information on folding and secondary structure, as 
has been widely applied for other conotoxins [32]. 
2.3 In vitro cRNA synthesis 
Plasmid constructs of rat α3 (pT7TS) and β4 (pNKS2) nAChR subunits were 
linearized with the XbaI restriction enzyme (NEB, Ipswich, MA, USA) for in vitro cRNA 
transcription using the T7/SP6 mMessage mMachine® transcription kits (AMBION, Forster 
City, CA, USA). 
2.4 Oocyte preparation and microinjection 
Stage V–VI oocytes were obtained from X. laevis, defolliculated with 1.5 mg/mL 
collagenase Type II (Worthington Biochemical Corp., Lakewood, NJ, USA) at room 
temperature (21−23 °C) for 1−2 h in OR-2 solution (82.5 mM NaCl, 2 mM KCl, 1 mM 
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MgCl2 and 5 mM HEPES at pH 7.4). Oocytes were injected with 5 ng cRNA of rat α3β4 
nAChR (α3:β4 = 10:1; concentration confirmed spectrophotometrically and by gel 
electrophoresis) using glass pipettes pulled from glass capillaries (3-000-203 GX, Drummond 
Scientific Co., Broomall, PA, USA). Oocytes were incubated at 18 °C in sterile ND96 
solution (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES at pH 7.4), 
supplemented with 5% fetal bovine serum, 0.1 mg/mL gentamicin (Gibco, Grand Island, NY, 
USA) and 100 U/mL penicillin-streptomycin (Gibco, Grand Island, NY, USA). 
2.5 Oocyte two-electrode voltage clamp recording and data analysis 
Electrophysiological recordings were carried out 2−5 days post cRNA microinjection. 
Two-electrode voltage clamp recordings were performed at room temperature using a 
GeneClamp 500B amplifier and pClamp9 software interface (Molecular Devices, Sunnyvale, 
CA, USA) at a holding potential of −80 mV. Voltage-recording and current-injecting 
electrodes were pulled from GC150T-7.5 borosilicate glass (Harvard Apparatus, Holliston, 
MA, USA) and filled with 3 M KCl, giving resistances of 0.3–1 MΩ. Oocytes were perfused 
with ND96 solution using a continuous Legato 270 push/pull syringe pump perfusion system 
(KD Scientific, Holliston, MA, USA) at a rate of 2 mL/min.  
Initially, oocytes were briefly washed with ND96 solution followed by three 
applications of 50 µM ACh for rat α3β4 nAChR (α3:β4 = 10:1) [10]. Washout with bath 
solution was done for 3 min between ACh applications. Oocytes were incubated with peptides 
for 5 min with the perfusion system turned off, followed by co-application of ACh and 
peptide with flowing bath solution. All peptide solutions were prepared in ND96 solution 
containing 0.1% bovine serum albumin. Peak current amplitudes before (ACh alone) and after 
(ACh + peptide) peptide incubation were measured using AxoGraph X software (Axograph 
Scientific, Berkeley, CA, USA), where the ratio of ACh + peptide-evoked current amplitude 
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to ACh alone-evoked current amplitude was used to assess the activity of the peptides at the 
rat α3β4 nAChR.  
All electrophysiological data were pooled (n ≥ 3) and represent means ± standard error 
of the mean. Data sets were compared using an unpaired Student’s t-test (GraphPad Software, 
La Jolla, CA, USA). Differences were regarded statistically significant when p < 0.05. The 
IC50 was determined from concentration-response curve fitted to a non-linear regression 
function and reported with error of the fit. 
2.6 Molecular modeling 
Molecular models of the interaction between AuIB and the ECD of rat α3β4 nAChR 
were built by homology with Modeller9v18 [33] using the following crystal structures as 
templates: (1) the complex between Aplysia californica acetylcholine-binding protein 
(AChBP) and conotoxin PnIA variant (PDB: 2BR8), and (2) the human α4β2 nAChR (PDB: 
5KXI). The complex between rAuIB and the ECD of (α3)3(β4)2 nAChR was modelled by 
assuming an interaction in the α3(+)α3(−) orthosteric binding site whereas the complex 
between gAuIB and the ECD of (α3)2(β4)3 nAChR was built by assuming an interaction in the 
α3(+)β4(−) orthosteric binding site. Similar to most other α-conotoxins rAuIB is a 
competitive inhibitor of the α3β4 nAChR, suggesting that it binds in the orthosteric binding 
site [10]. In contrast, α-conotoxin gAuIB inhibits non-competitively the α3β4 nAChR [10] but 
it was shown to nevertheless bind to the orthosteric binding site [34]. This latter study 
unequivocally identified that gAuIB binds at the α3(+)β4(−) interface using 
electrophysiological recording of nAChRs expressing β4 subunit mutants. As an explanation 
to the non-competitive nature of the inhibition, gAuIB was proposed to stabilize the 
desensitized state of α3β4 nAChR [34]. It was previously demonstrated using single channel 
recording that another antagonist, DHβE, stabilized the desensitized state of an nAChR [35], 
despite binding in the orthosteric binding site [36].  
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The molecular models were refined by a 50 ns molecular dynamics simulation in 
explicit water using the GROMACS 5.1.4 package [37] and the Amber99SB-ILDN protein 
force field [38], as described previously [39,40]. Briefly, the systems were gradually heated 
from 50 to 300 K at constant volume and then simulated with constant pressure while 
gradually removing the restraints imposed on the protein and peptide atoms. All bonds 
involving hydrogen atoms were constrained with the LINCS algorithm, allowing the use of a 
2 fs time step. The particle-mesh Ewald method was used to compute long-range electrostatic 
interactions. The models of complexes involving two rAuIB mutants, [S4A]rAuIB and 
[F9A]rAuIB, were initially generated by substituting residue side chains using Modeller9v18 
and then carrying out molecular dynamics simulations as described above. The backbone 
root-mean-square deviation from the starting conformation was stable over the last 20 ns of 
the simulations and this period was used for analysis. The solvent accessible surface area was 
calculated using the GROMACS package with a probe radius of 1.4 Å. Additional 200 ns 
molecular dynamics simulations were also carried out using similar set-up for rAuIB and 
[P7A]rAuIB in the absence of the receptor. Secondary structure analyses of these simulations 
were computed using the DSSP program [41] and the GROMACS package.  
Results 
3.1 Peptide synthesis and oxidative folding  
We designed a suite of mutants in which all non-Cys residues of rAuIB were 
separately substituted by Ala to identify the positions that are important for inhibition of the 
α3β4 nAChR (Table 1). All the Ala mutants of rAuIB as well as rAuIB, gAuIB and 
[P7A]gAuIB were successfully synthesized with orthogonal protection of the cysteine side 
chains to orient the folding toward a unique disulfide isomer. 
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3.2 [P7A]rAuIB has more similar secondary Hα chemical shifts to gAuIB than rAuIB 
Secondary Hα chemical shifts analysis, which is useful for deducing secondary 
structure elements, was conducted for gAuIB, rAuIB and all mutants (Fig. 2). The Hα 
secondary chemical shifts of rAuIB synthesized in this study were in agreement with 
previously reported values [8], indicating that the fold of rAuIB is the same as in previous 
studies. Apart from some local changes in chemical shift at the substitution site, all mutants 
displayed a similar pattern of shifts to the parent peptide except [P7A]rAuIB (Fig. 2C). 
Interestingly, residues from Pro6 to Phe9 of [P7A]rAuIB had negative secondary Hα chemical 
shifts (Fig. 2C), indicating that this segment adopts an α-helical structure, a motif that exists 
in the globular isomer but not in the ribbon isomer. The P7A substitution therefore seems to 
have improved the definition of the structure of rAuIB, with the parent peptide being devoid 
of stable regular secondary structure. The retention time and secondary Hα chemical shifts 
between [P7A]rAuIB and [P7A]gAuIB were different, excluding the possibility that 
[P7A]rAuIB converted into [P7A]gAuIB during the folding process (Fig. 2D). To further 
substantiate this difference of conformation, we carried out two 200 ns molecular dynamics 
simulations: one simulation starting from the NMR solution structure of rAuIB, and the 
second from a model of the P7A variant, which was created by simple side chain swaps in the 
NMR structure of rAuIB. Consistent with the NMR measurements, the simulation of 
[P7A]rAuIB suggested the existence of a stable α-helix from Pro6 to Phe9 (Fig. 2E). 
Interestingly, the P7A variant was more rigid than the parent peptide, as measured using the 
root-mean-square fluctuation (Fig. 2F). 
3.3 Several rAuIB analogues have decreased potency at rat α3β4 nAChR 
All peptides were tested for inhibition of the rat α3β4 nAChR subtype heterologously 
expressed in X. laevis oocytes. In the first round of electrophysiological experiments, all 
rAuIB Ala mutants were tested at 1 µM (corresponding to the reported IC50 of rAuIB [10]) 
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and gAuIB was tested at 3 µM, resulting in 30–40% inhibition of ACh-evoked currents of rat 
α3β4 (α3:β4 = 10:1) nAChR (Fig. 3A). The rAuIB Ala mutants exhibited comparable activity 
to the parent peptide except for [S4A] and [F9A]rAuIB, which caused 25% and 20% 
inhibition, respectively (Fig. 3A). Comparison of the rat α3β4 nAChR inhibition by [S4A] 
and [F9A]rAuIB  indicates that the difference was not statistically significant. In the second 
round, all peptides were tested at 100 µM, inhibiting 35–55% of ACh-evoked currents of rat 
α3β4 (α3:β4 = 10:1) nAChR (Fig. 3A). Mutation at S4, P6, F9, T11, N12 and D14 caused a 
decrease in activity, ca. 40% inhibition, whereas other peptides had higher activity, with 45–
55% inhibition (Fig. 3B and C). The efficacy (maximum inhibition of ACh-evoked currents) 
of rAuIB was ~55%, which is ~15% lower than reported previously [10]. This difference may 
arise from variations in the relative levels of expression of α3 and β4 subunits in different 
batches of oocytes.  
In summary, none of the single position variants displayed a dramatic loss of activity 
compared to the parent peptide. The Ala substitution of six positions in rAuIB led to a 
decreased activity at high concentration, but only two substitutions, S4A and F9A, 
significantly impacted activity at a concentration similar to the IC50 of rAuIB, suggesting they 
are more important for antagonizing the activity of rat α3β4 nAChR. To better quantify the 
loss of activity, we calculated the IC50 of [S4A]rAuIB at the α3β4 nAChR (α3:β4 = 10:1) to 
be 442 ± 99 nM (Fig. 3D); the IC50 of rAuIB was previously reported to be 860 nM at the 
same receptor stoichiometry [10]. Considering the variability between different 
electrophysiological set-ups, we consider that inhibition by rAuIB and [S4A] rAuIB are of the 
same order of magnitude, i.e., the S4A substitution caused a less than 10-fold drop decrease in 
inhibition. 
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3.4 rAuIB adopts a binding mode similar to that of globular α-conotoxins 
Since the functional data indicated that rAuIB inhibits the α3(+)α3(−) interface of the 
(α3)3(β4)2 nAChR [10] we built molecular models of the interaction between the α3(+)α3(−) 
binding site and rAuIB. This model was refined using molecular dynamics simulations and 
used to propose explanations for the SAR data. A molecular model of the interaction between 
gAuIB and the α3(+)β4(−) binding site was built similarly to that of rAuIB for comparison 
purposes. The molecular interactions between the peptides and the receptors were monitored 
over the last 20 ns of each 50 ns simulation. This period of 20 ns, during which the system 
reached equilibrium, is referred to as the “simulation time”. 
3.4.1 Binding mode of gAuIB at the rat α3β4 nAChR 
The G1A, P6A and F9A mutants of gAuIB are reported to display decreased inhibitory 
activity at rat α3β4 nAChR compared to gAuIB [34]. The molecular model of the complex 
between gAuIB and the α3(+)β4(−) binding site (Fig. 4A), which is very similar to a reported 
molecular model of the same system [34], can be used to suggest rational explanations to the 
consequence of these substitutions. The positively charged N-terminus (Gly1) is in the 
proximity of the negatively charged side chain oxygen atoms of D168 and D169 in the 
simulation, with an average distance of 3.9 Å and 2.8 Å. A stable salt bridge was established 
between D169 and the N-terminus during the simulation time and a similar interaction was 
transiently formed between D169 and the N-terminus. Therefore, a substitution of this first 
residue of the toxin by Ala could change the peptide backbone conformation and prevent the 
establishment of these salt bridges.  
Pro6 is a highly conserved residue among α-conotoxins because it anchors the 
conotoxins into an aromatic pocket on the nAChR that is important for the interaction 
between nAChR and agonists [42]. It is therefore not surprising that the substitution of Pro6 
by Ala caused a decrease in activity. The side chain of Phe9 is embedded in a hydrophobic 
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pocket formed by K57, E59, Q117 and L119 of the β4 subunit, and the backbone oxygen of 
Phe9 formed a hydrogen bond with the receptor Q117 during 85% of the simulation time. The 
substitution of the bulky Phe9 by an Ala, which has a smaller side chain, would cause a 
change in shape complementarity at the interface, possibly resulting in a reorientation of the 
peptide in the binding pocket (similar to [F9A]rAuIB described below). 
3.4.2 Binding mode of rAuIB at the rat α3β4 nAChR 
Our molecular models suggest that the conformation adopted by rAuIB when bound to 
the rat α3β4 nAChR is similar to that of gAuIB except for the N- and C- termini (Fig. 4B). 
The interactions established by the first loop of AuIB are similar for the two isomers, and this 
loop sits deeply in the orthosteric binding site of the α3β4 nAChR. The first disulfide bond 
(i.e., Cys I-Cys III for gAuIB and Cys I-Cys IV for rAuIB) packs similarly against the vicinal 
disulfide bond of the C-loop, and this interaction is a conserved feature in the crystal 
structures of α-conotoxins/AChBP. Because of this interaction, the different disulfide 
connectivities of the two isomers resulted in different peptide conformation and disparate 
location of their N- and C- termini within the nAChR binding site. The charged N-terminus, 
(Gly1) interacts with the acidic residues of the F-loop of α3β4 nAChR in the gAuIB model 
(Fig. 4A) but not in the model of rAuIB (Fig. 4B). The location of the amidated C-terminus in 
the nAChR binding site is also different between the two isomers; this difference results from 
the different conformation of the second loop.  
We have shown the side chains of Ser4 and Phe9 in rAuIB are the most important for 
activity at the rat α3β4 nAChR. As shown in Fig. 4B, Ser4 of rAuIB establishes a stable side 
chain-side chain hydrogen bond with D169 (98% of the simulation time). Additionally, Ser4 
forms transient hydrogen bonds with S36 and N166 (40% of the simulation time). Phe9 of 
rAuIB interacts with the α3(−) subunit: it forms a hydrogen bond with K57 through its 
backbone oxygen during 93% of the simulation and its side chain contacts the residues E34, 
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S36, W55, K57 and I119. The distance between the heavy atoms of Phe9 and of the 
aforementioned residues of the α3(−) subunit were below 5.0 Å, the distance considered to 
define a contact.  
Positions 11, 12 and 14 of rAuIB caused a small drop of inhibition when mutated to 
Ala. These three residues are located at the interface with the receptor in the binding model 
but their side chains are also solvated, suggesting that their contribution to the electrostatic 
component of the binding energy is at best weak. Indeed, their involvement was only detected 
experimentally at the highest concentration (100 µM). By contrast, the impact of the 
substitutions S4A and F9A were detected at the lower concentration of 1 µM. We further 
studied the impact of these two substitutions on the binding mode by carrying out further 
molecular dynamics simulations. 
3.4.3 Binding mode of [S4A]rAuIB at the rat α3β4 nAChR 
The binding mode resulting from the 50 ns molecular dynamics simulation of 
[S4A]rAuIB displayed subtle variations from that of the parent peptide, with differences 
mainly located in the proximity of the modified position 4 (Fig. 4C). Besides position 4, all 
positions at the interface with the β4 subunit, such as Phe9, established similar molecular 
interactions in the S4A mutated model. The simulation suggests that the loss of the hydrogen 
bond between Ser4 and D169 is compensated by the establishment of a hydrogen bond 
between the side chain of α3(−) K168 and the backbone oxygen of the toxin Cys2, which was 
stable for 89% of the simulation time. The conformation of the side chain of K168 of the 
receptor seems to be also stabilized by electrostatic interactions with the D169 side chain. 
This electrostatic interaction was not possible in the rAuIB model because D169 was engaged 
in a hydrogen bond with Ser4 and consequently maintained away from K168 (Fig. 4B and C). 
The transient hydrogen bonds between Ser4 and α3(−) S36/N166 established in the model of 
rAuIB were not compensated in the mutated model of [S4A]rAuIB. Therefore, we suggest 
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that [S4A]rAuIB displays overall fewer hydrogen bonds with the receptor than the parent 
peptide. Based on electrophysiological measurements, we proposed that the decrease in 
activity was lower than 10-fold, corresponding to a loss of less than 1.4 kcal/mol. This energy 
is typical of a weak hydrogen bond interaction, which is consistent with the 40% occurrence 
of the hydrogen bonds between Ser4 and S36/N166 during the molecular dynamics 
simulations. 
3.4.4 Binding mode of [F9A]rAuIB at the rat α3β4 nAChR 
According to the molecular model of rAuIB bound to the α3(+)α3(−) binding site, 
Phe9 is buried at the interface with the receptor. Its substitution by Ala creates a gap between 
the α3(−) subunit and the peptide in the initial step of the simulation. During this simulation, 
the peptide reoriented slightly in the binding site, resulting in several changes of pairwise 
interactions and a slight outward reorientation of the C-loop (Fig. 4D). Globally, the F9A 
variant had fewer contacts with the receptor than the parent peptide, as evidenced by a 
decrease in buried surface area from 1646 Å2 to 1452 Å2. As a result of the slight shift in 
orientation, the backbone oxygen of Ala9 only forms a transient hydrogen bond (42% of the 
simulation time) with the side chain of K57, whereas this interaction was present during 93% 
of the simulation time for the parent peptide. Similarly, the hydrogen bond between Ser4 
(rAuIB) and D169 (α3 subunit) of the receptor was only observed during 75% of the 
simulation time compared to 98% for the parent peptide. We therefore propose that the F9A 
substitution caused a slight shift of the binding mode, resulting in fewer contacts and 
hydrogen bonds at the interface. 
Discussion 
The surprising discovery that the ribbon isomer of an α-conotoxin displays higher 
potency than the corresponding globular isomer [8] contrasts with the previously held 
assumption that native (globular) disulfide isomers have optimal activity. We carried out a 
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complete Ala scan of rAuIB, discovering the side chains of two positions, Ser4 and Phe9, 
were the most important for activity against the rat α3β4 nAChR. We have rationalized these 
data by proposing a binding mode between rAuIB and α3β4 nAChR. Molecular dynamics 
simulation suggested that rAuIB adopts a well-defined conformation when bound to its 
molecular target and that the binding mode is highly stable. A number of other SAR studies 
have been conducted on globular α-conotoxins [14], and we compared our results to these 
studies to further evaluate the molecular model of rAuIB binding mode. 
Position 1 was identified to be important for gAuIB activity at the α3β4 nAChR [34] 
but this was not the case for rAuIB (this study), paralleling the contrasting role of this position 
observed in several other studies on α-conotoxins. As for rAuIB, the G1A substitution had no 
impact on the inhibition of α7 nAChR by α-conotoxin ImI [43], and a minor impact on the 
affinity of α-conotoxin MII for the α3β2 nAChR (< 5-fold difference) [44]. A molecular 
model of the interaction between ImI and the α7 nAChR indeed suggested that ImI Gly1 does 
not interact with the receptor [40], similar to our model of the rAuIB/α3β4 nAChR complex. 
In contrast, the G1A mutation of α-conotoxin TxID resulted in a ~20-fold decreased activity at 
the α3β4 nAChR [45], and the same substitution caused a significant decrease in activity for 
α-conotoxin gAuIB at the α3β4 nAChR [34]. The molecular models of the corresponding 
complexes suggested that the N-terminus of these peptides potentially forms a salt bridge with 
negatively charged residues located in the F-loop of the receptor [34,45], as in our model of 
the gAuIB/α3β4 nAChR complex. 
The S4A substitution impacted the activity of rAuIB at the α3β4 nAChR, but it was 
reported not to affect that of gAuIB [34]. As for gAuIB, this substitution had no effect on the 
activity or affinity of α-conotoxin RgIA at α9α10 [46], ImI at α7 [43,47], PeIA at α3β2 and 
α6/α3β2β3 [48], BuIA at α6/α3β2β3 [49] and TxID at α3β4 nAChRs [45]. Only a small 
decrease of inhibition of five- to eight-fold was reported after a substitution equivalent to S4A 
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in GID* (S7A for GID*) and MII at the α4β2 and α3β2 nAChRs, respectively [44,50,51]. 
TxID Ser4 was suggested to have no interaction with the receptor using molecular modeling, 
explaining that its substitution to Ala was innocuous [45]. In contrast, a molecular model of 
the complexes involving GID* and the α4β2 nAChR suggested that the Ser side chain 
potentially forms a hydrogen bond with an Asp residue in the F-loop of the receptor [52], 
similar to our model of the rAuIB/α3β4 nAChR complex.  
Pro6 is highly conserved among all α-conotoxins and typically interacts with the 
aromatic box, which is a conserved ACh interaction site in the nAChR and AChBP orthosteric 
binding sites [53–55]. Pro6 is also important for stabilizing the structure of globular α-
conotoxins: replacing this Pro with Ala typically results in a change of conformation linked to 
a decrease or loss of activity. For example, the P6A substitution of α-conotoxin PeIA caused a 
20-fold decrease of inhibition of the α6/α3β2β3 nAChR compared to the parent peptide [48]. 
The P6A substitution of α-conotoxins ImI and MI resulted in a 50–70 fold decrease in affinity 
for the α7 and muscle type nAChRs, respectively [43,47,56], whereas this substitution caused 
a >700-fold decrease in activity for α-conotoxin MII at the α3β2 nAChR [44,50]. The same 
substitution resulted in a loss of helical content for globular Vc1.1 and a marked decrease in 
inhibitory activity of α-conotoxin Vc1.1 [57]. Similarly, the P6A substitution of gAuIB 
resulted in a decrease in secondary structure content as well as a complete loss of inhibitory 
activity [34]. In contrast, [P6A]rAuIB showed only a small decrease in activity compared to 
the parent peptide. Our molecular models suggest that Pro6 of rAuIB and gAuIB should make 
similar interactions with the receptor and we propose that the different impact that P6A 
substitution had on the activity of the two peptides arises from its differential effect on the 
peptide structures. Indeed, P6A substitution destabilizes the small α-helical motif required for 
the activity of gAuIB. In contrast, as rAuIB already lacks regular secondary structure, P6A 
does not further impact its propensity to adopt the α-helical content required for binding to the 
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receptor. The substantial decrease in inhibitory activity of gAuIB resulting from P6A 
substitution appears therefore to result primarily from the change of conformation of the 
peptide rather than decreased interactions of the position 6 side chain at the interface. 
The only rAuIB variant that displayed different Hα secondary chemical shifts from the 
parent peptide was [P7A]rAuIB, indicating that this variant adopts a different fold in solution. 
NMR spectroscopy data suggest that [P7A]rAuIB adopts a helical structure, whereas rAuIB 
lacked regular secondary structure and was globally less structured. A possible explanation for 
this change of conformation is that Ala residues promote the formation of α-helices, whereas 
Pro residues typically destabilize regular secondary structure elements. BuIA is the only other 
α-conotoxin that has a similar cysteine scaffold to AuIB and had its ribbon isomer studied by 
NMR spectroscopy [58]. As for ribbon AuIB, ribbon BuIA displays Pro residues at positions 6 
and 7. The ribbon isomer of BuIA also has a more flexible backbone than the globular isomer 
and does not form the α-helix that is a conserved feature of α-conotoxin globular isomers. It 
would be interesting to study the influence of the P7A substitution on the structure of ribbon 
BuIA because this substitution could increase the helical content similarly to rAuIB. In our 
molecular models, rAuIB interacts with the receptor using a conformation that is stabilized by 
the P7A substitution, suggesting that the binding energy of the variant would benefit from a 
more favourable entropy term than the parent peptide. Nevertheless, the activity of the mutant 
was not experimentally different from the parent peptide, which could be interpreted by the 
loss of a number of contacts between the Pro side chain and the receptor. 
The substitution of position 9 with Ala caused a decrease in affinity for both gAuIB 
[34] and rAuIB (this work). Position 9 of globular α-conotoxins is buried at the interface with 
the complementary subunit and has been identified as important for modulating the activity of 
a range of globular α-conotoxins [34,45,46,49,51,57]. For example, Ala mutation at this 
position caused a 50-fold decrease in activity of α-conotoxin GI at the muscle type nAChR 
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[59], a 20–30 fold decrease in affinity of α-conotoxin MII at α3β2 nAChR [44,50], and a >17-
fold decrease in activity of α-conotoxin GID* at α4β2 nAChR [51]. In addition, the R9A 
substitution resulted in a 1500-fold decrease in activity of RgIA at α9α10 nAChR [46]. 
Substitution of position 9 can also enhance activity, with the [S9A]PeIA displaying three-fold 
lower IC50 than the parent peptide at the α3β2 nAChR [48] and the [N9W]Vc1.1 and 
[N9A]Vc1.1 increasing activity by 20- and 30-fold at the human α9α10 nAChR compared to 
Vc1.1, respectively [39,57]. Several molecular models have been built to explain the ability of 
α-conotoxin position 9 to modulate nAChR inhibition, which suggest this residue interacts 
with various positions of the complementary subunit depending on the conotoxin and nAChR 
subtype [39,52,60]. In the proposed binding mode of rAuIB, Phe9 mainly interacts with β4 
K57, whereas GID* Arg12 was proposed to interact with β2 position 59 [52], [N9W]Vc1.1 
Trp9 with α10 W118 [39] and RgIA Arg9 with α10 W81 [60]. 
In summary, we have identified a number of positions crucial for the activity of the 
ribbon isomer of AuIB that are also important for the activity of gAuIB and/or other globular 
α-conotoxins, indicating rAuIB has a globally similar binding mode to the globular isomers of 
α-conotoxins. According to our models, the main difference between the ribbon and globular 
AuIB at the interface with α3β4 nAChR is at their N- and C- termini. Changing the disulfide 
connectivity of α-conotoxins from a globular to ribbon isomer therefore does not introduce a 
dramatic change of binding mode at the interface with the receptor but it does create some 
different interactions that can have a substantial impact on the selectivity, as is the case for 
AuIB. Ribbon isomers should therefore be more systematically considered in the design of 
molecular probes and specific inhibitors of nAChR subtypes based on α-conotoxins. 
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Figure legends 
Fig. 1. Overview of the three-dimensional structure of nAChRs, the two main stoichiometries 
of α3β4 nAChRs, the three disulfide isomers of AuIB and the NMR spectroscopy solution 
structures of ribbon AuIB (rAuIB) and globular AuIB (gAuIB). A: The structure of nAChRs 
comprises three domains: an extracellular domain (ECD), a transmembrane domain (TMD), 
and an intracellular domain (ICD; ICD has not been resolved in the crystal structure). An 
arrow indicates the direction of cation movement through the central pore. The ribbon 
representation of the nAChR used the coordinates from the X-ray crystallography structure of 
the α4β2 nAChR (PDB: 5KXI). The membrane is represented by a purple rectangle and the 
extracellular (Ext.) and intracellular (Int.) sides of the membrane are indicated. B: Structure of 
the agonist binding site in the ECD, which is at the interface between a “principal” subunit 
(green) and a “complementary” subunit (cyan). The binding site is occupied by nicotine 
(orange). The ECD of each subunit displays one α-helix and 10 β-strands (β1 to β10), and the 
A-, B- , C- and F-loops are indicated. C: Illustration of the two main stoichiometries of 
homopentameric α3β4 nAChRs and identification of the functional binding sites. The 
illustration represents the nAChR as seen from the extracellular side and parallel to the 
membrane; the pore is in the center of the pentamer. The C-loop of each subunit is indicated 
by a curved line. The α3(+)β4(−) and α3(+)α3(−) agonist binding sites are indicated by orange 
and green discs, respectively. D: Amino acid sequence of the disulfide isomers of AuIB. Cys 
residues are numbered with Roman numerals (I–IV) and the disulfide bonds are shown as 
orange sticks. E: Three-dimensional NMR solution structures of gAuIB (PDB: 1MXN) and 
rAuIB (PDB: 1MXP). 
 
Fig. 2. Secondary Hα chemical shifts (∆δHα) of gAuIB, rAuIB and their variants (panels A, B 
and C) and analysis of the conformation of [P7A]rAuIB (panels D, E and F). A, B and C: 
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Secondary Hα chemical shifts of gAuIB, [P7A]gAuIB, rAuIB, and the rAuIB variants. The 
sequence of AuIB is indicated at the bottom. The dashed lines at 0.1 ppm and -0.1 ppm 
indicate the cut-off considered for assessing regular secondary structure content (above 0.1 
ppm is β-strand and under -0.1 ppm is α-helix). D: Co-elution profile by reversed-phase 
HPLC of [P7A]rAuIB and [P7A]gAuIB monitored by absorbance at 214 nm. E: Secondary 
structure content of rAuIB and [P7A]rAuIB monitored over 200 ns molecular dynamics 
simulations. The positions in the sequence are on the y-axis. The secondary structure around 
position 7 is highlighted using a red dashed line. F: Root-mean-square fluctuation (RMSF) of 
the Cα of each position of rAuIB and [P7A]rAuIB over 200 ns molecular dynamics 
simulations. The RMSF was computed by fitting the Cα of the molecules to the first frame of 
each simulation.  
 
Fig. 3. Activity of gAuIB, rAuIB and alanine mutants of rAuIB at the rat α3β4 nAChR. A and 
B: Bar graphs showing relative ACh-evoked peak current inhibition of rat α3β4 nAChR 
(α3:β4 = 10:1) by rAuIB analogues and gAuIB compared with rAuIB. In A, the peptides were 
tested at 1 µM, except gAuIB (3 µΜ). In B, the peptides were tested at 100 µM. The dashed 
lines indicate relative current amplitude in the presence of rAuIB. C: Superimposed 
representative traces of ACh-evoked currents mediated by rat α3β4 nAChR in the absence 
(black) and presence (red) of 1 µM (left) or 100 µM (right) [S4A]rAuIB. D: Concentration-
response relationship of relative ACh-evoked current amplitude mediated by rat α3β4 nAChR 
(α3:β4 = 10:1) in the presence of [S4A]rAuIB (10 nM−100 µM) giving an IC50 of 
441.8 ± 98.5 nM. Whole-cell currents at rat α3β4 were activated by 50 µM ACh. Relative 
current amplitude values are mean ± standard error of the mean; n = 5−9. The difference 
between the relative current amplitude of rAuIB and each variant was evaluated using the 
unpaired Student’s t-test; * indicates a p < 0.05. 
33 
 
 
Fig. 4. Molecular models of complexes between α3β4 nAChR and gAuIB (A), rAuIB (B), 
[S4A]rAuIB (C), or [F9A]rAuIB (D). The evolution of a selection of distances indicative of 
hydrogen bonds between pairs of residues at the interface is shown at the bottom for each 
model. The α3(+) subunit is shown in green, the α3(−) or β4(−) subunit is shown in cyan, the 
peptides are shown in orange, and the disulfide bonds are shown in yellow. Hydrogen bonds 
monitored in the bottom panel are displayed as dotted black lines on the structure. Interactions 
between charged side chains are circled with a dotted red line. The distances were evaluated 
during the last 20 ns of each molecular dynamics simulation. The label for each distance 
comprises the residue of the toxin followed by the residue of the receptor. A dashed line at 
3.2 Å indicates the upper-limit between the donor and acceptor atoms involved in a hydrogen 
bond. Panel B inset shows an overlay of the binding modes of rAuIB (orange) and gAuIB 
(white). Panel D inset shows that the C-loop in the [F9A]rAuIB molecular model (orange) 
moves outward compared to the C-loop in the model of the rAuIB/α3β4 nAChR complex 
(white). 
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Table 1. Amino acid sequences of gAuIB, rAuIB and variants synthesized and characterized 
in this study. 
Peptide name Sequence Theoretical massa Observed massa 
gAuIB GCCSYPPCFATNPDC-NH2 1572.8 1572.2 
rAuIB GCCSYPPCFATNPDC-NH2 1572.8 1572.4 
[G1A]rAuIB ACCSYPPCFATNPDC-NH2 1586.8 1586.6 
[S4A]rAuIB GCCAYPPCFATNPDC-NH2 1556.8 1556.6 
[Y5A]rAuIB GCCSAPPCFATNPDC-NH2 1480.7 1480.3 
[P6A]rAuIB GCCSYAPCFATNPDC-NH2 1546.7 1546.4 
[P7A]rAuIB GCCSYPACFATNPDC-NH2 1546.7 1546.4 
[F9A]rAuIB GCCSYPPCAATNPDC-NH2 1496.7 1496.3 
[T11A]rAuIB GCCSYPPCFAANPDC-NH2 1542.8 1542.4 
[N12A]rAuIB GCCSYPPCFATAPDC-NH2 1529.8 1529.4 
[P13A]rAuIB GCCSYPPCFATNADC-NH2 1546.8 1546.4 
[D14A]rAuIB GCCSYPPCFATNPAC-NH2 1528.8 1528.4 
[P7A]gAuIB GCCSYPACFATNPDC-NH2 1546.7 1546.2 
a Average mass in Dalton. 
 
 
 
 
